Novo Nordisk's New Obesity Drug Fails a Big Test

Novo Nordisk just learned its latest much-hyped obesity drug may not actually live up to the hype. Shares of the Danish pharma giant plunged 16% Monday after it reported that its experimental drug, CagriSema, did not match the weight loss achieved by Eli Lilly's rival drug in a direct comparison...